1.- CEAMED MISSION & 2012 OBJECTIVES

Docking de betalap en tres bolsillos de topoII

CEAMED S.A. project is the creation of a company of University origin chiefly oriented to the research and development of new drugs (antitumor and other types)

CEAMED S.A. activities are based on two divisions i.e. NEW ANTICANCER (R&D) and GENERIC DRUGS.

1.1.- MISSION OF THE R&D DIVISION:

Discovery, development and production of original drugs in the Canary Islands for the international pharmaceutical industry, obtained from or inspired on natural products taken from the rich biodiversity of the Macaronesian regions.

R&D DIVISION OBJECTIVES FOR 2012

Have available an original CEAMED S.A. drug, preferably an anticancer one, which had entirely completed the preclinical studies and would be ready to enter clinical studies, and being attractive enough to the multinational pharmaceutical industry.

 

1.2.- MISSION OF THE GENERIC DRUGS DIVISION:

Marketing and production of generic drugs from the Canary Islands for the local, national and African markets, aiming to invest 15% of its benefits into the development of CEAMED S.A. new original drugs (R&D Division).

DIVISION OF GENERIC DRUGS OBJECTIVES FOR 2012

To have licence as Pharmaceutical Laboratory (2010) and a portfolio of 10 generic drugs, each achieving at least 15% of the Canary market, with steady introduction in the African market, and as a whole, allow to finance the general expenses of the company and provide at least 25% of the finances required for the production of new drugs.

 

1.3.-COMPANY PROFILE

CEAMED S.A. is a biopharmaceutical company created in 2006 by 12 scientists, most of them related to the Canary Islands Cancer Research Institute (www.icic.es).  It is a Spin-off company of the two Canary Universities i.e. University of La Laguna (www.ull.es) and University of Las Palmas de Gran Canaria (www.ulpgc.es), with whom it has signed collaboration agreements.

CEAMED S.A. focuses its activity on the discovery and development of small organic molecules as drugs for the treatment of cancer and other diseases.

CEAMED S.A. is based on the scientific capacity of its founders and partners, as well as its human resources, to thus obtain new organic compounds from the rich biodiversity of the Canary Islands and its surrounding ocean.

CEAMED S.A. trusts in the experience of its professional team to evaluate the bioactivities of the selected compounds, as well as in their clinical experience, which would guide the Company’s decisions, aiming at discovering new anticancer agents together with the design of new cancer therapies.

 

1.4.- BUSINESS STRATEGY

CEAMED S.A. has adopted a Business Model that has been very successful for the development of new anticancer drugs.  It begins with the isolation and identification of natural products with shown anticancer activity. It then continues with the improvement of the cytotoxic profile of the compounds by means of semisynthetic or biotechnological modifications.

After these, and in order to obtain the proof of concept to complete the preclinical studies, the action mechanism(s), as well as their pharmacodynamic properties, toxicity and effectiveness on animal models are studied.  Once this stage is reached, CEAMED S.A. searches for appropriate partners in the international market for the subsequent clinical development of the drugs.

CEAMED S.A. estimates that the long run strategy of the company and its R&D Division success depend upon a continuous supply of funds, coming either from public calls through competitive projects submitted by its associates or scientific team, together with the financial contributions of its shareholders and associates, as well as its Generic Drugs Division, the latter devoting a maximum of 15% of its benefits.